Cellectar director granted 25,000 stock options

Cellectar Biosciences director Asher Chanan-Khan received a grant of stock options covering 25,000 shares of common stock.

Rhea-AI Filing Summary

Cellectar Biosciences director Asher Chanan-Khan received a grant of stock options covering 25,000 shares of common stock. The options have an exercise price of $2.70 per share and expire on July 7, 2036. According to the terms, the entire grant will vest on July 7, 2027, provided he continues to serve through that date. Following this grant, his reported holdings include 25,000 stock options directly.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Chanan-Khan Asher

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	25,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 25,000 contracts (Direct)

Footnotes (1)

1. F1. This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.

Key Figures

Options granted: 25,000 options Exercise price: $2.70 per share Expiration date: July 7, 2036 +2 more

5 metrics

Options granted 25,000 options Stock option grant to director Asher Chanan-Khan

Exercise price $2.70 per share Strike price for the 25,000 stock options

Expiration date July 7, 2036 Options expire if not exercised by this date

Vesting date July 7, 2027 Options vest in full on this date, subject to service

Options held after grant 25,000 options Total reported derivative holdings following transaction

Key Terms

Stock option (right to buy), exercise price, expiration date, vest in full, +1 more

5 terms

Stock option (right to buy) financial

"security_title: "Stock option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "2.7000" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-07-07T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in full financial

"This option shall vest in full on July 7, 2027"

continued service financial

"subject to the reporting person's continued service through the applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cellectar Biosciences (CLRB) report for Asher Chanan-Khan?

Cellectar Biosciences reported a grant of stock options to director Asher Chanan-Khan. He received options on 25,000 shares of common stock as compensation, not a market purchase, with a defined exercise price and long-term expiration date.

How many Cellectar Biosciences (CLRB) options were granted to Asher Chanan-Khan?

Asher Chanan-Khan was granted stock options on 25,000 shares of Cellectar Biosciences common stock. This entire amount is tied to a single grant and represents his reported option position following the transaction on the Form 4 filing date.

What is the exercise price of Asher Chanan-Khan’s CLRB stock options?

The exercise price of the granted stock options is $2.70 per share. This means he can buy Cellectar Biosciences common stock at $2.70 if the options vest and are exercised before they expire, subject to the vesting conditions.

When do Asher Chanan-Khan’s Cellectar Biosciences options vest?

The options will vest in full on July 7, 2027. Vesting is conditional on his continued service with Cellectar Biosciences through that date, so the grant is structured as long-term, service-based compensation for his role as a director.

When do Asher Chanan-Khan’s CLRB stock options expire?

The granted stock options expire on July 7, 2036. After this expiration date, any unexercised options become worthless, so potential use of this award is limited to the period between vesting in 2027 and expiration in 2036.

Did Asher Chanan-Khan buy or sell CLRB shares in the market?

The Form 4 reports a grant of stock options, not an open-market trade. The transaction is classified as a grant or award acquisition, meaning it reflects equity-based compensation rather than a discretionary purchase or sale of Cellectar Biosciences shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 09:09 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chanan-Khan Asher

(Last) (First) (Middle)

C/O CELLECTAR BIOSCIENCES, INC.

100 CAMPUS DRIVE

(Street)

FLORHAM PARK NEW JERSEY 07932

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$2.7	07/07/2026		A		25,000		(1)	07/07/2036	Common stock	25,000	$0	25,000	D

Explanation of Responses:

1. This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Asher Chanan-Khan	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)